The phase I study is the first step to analyse the tolerance, determine the recommended dose of the combination, and explore the impact of GS5745 on MMP-9 plasma levels and multimodal imaging in patients with recurrent glioblastoma (NCT03631836). The gene discussed is MMP9; the disease is glioblastoma.